BIOFRONTERA AG (BFRA) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:BFRA

2.67
-0.28 (-9.49%)
Last: Mar 4, 2022, 08:19 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

Overall BFRA gets a fundamental rating of 1 out of 10. We evaluated BFRA against 523 industry peers in the Biotechnology industry. BFRA has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, BFRA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year BFRA has reported negative net income.
BFRA Yearly Net Income VS EBIT VS OCF VS FCFBFRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 -10M -20M -30M

1.2 Ratios

Industry RankSector Rank
ROA -22.64%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BFRA Yearly ROA, ROE, ROICBFRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 -100 -200 -300 -400

1.3 Margins

Industry RankSector Rank
OM -42.23%
PM (TTM) -55.98%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BFRA Yearly Profit, Operating, Gross MarginsBFRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • The number of shares outstanding for BFRA has been increased compared to 1 year ago.
  • The debt/assets ratio for BFRA is higher compared to a year ago.
BFRA Yearly Shares OutstandingBFRA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 10M 20M 30M 40M
BFRA Yearly Total Debt VS Total AssetsBFRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -2.09, we must say that BFRA is in the distress zone and has some risk of bankruptcy.
  • A Debt/Equity ratio of 0.13 indicates that BFRA is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Altman-Z -2.09
ROIC/WACCN/A
WACCN/A
BFRA Yearly LT Debt VS Equity VS FCFBFRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 0 10M -10M 20M -20M -30M

2.3 Liquidity

  • BFRA has a Current Ratio of 1.26. This is a normal value and indicates that BFRA is financially healthy and should not expect problems in meeting its short term obligations.
  • A Quick Ratio of 1.13 indicates that BFRA should not have too much problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.26
Quick Ratio 1.13
BFRA Yearly Current Assets VS Current LiabilitesBFRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 23.53% over the past year.
  • BFRA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -15.27%.
  • Measured over the past years, BFRA shows a very strong growth in Revenue. The Revenue has been growing by 48.96% on average per year.
EPS 1Y (TTM)23.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.67%
Revenue 1Y (TTM)-15.27%
Revenue growth 3Y36.15%
Revenue growth 5Y48.96%
Sales Q2Q%14.13%

3.2 Future

  • The Earnings Per Share is expected to grow by 12.07% on average over the next years. This is quite good.
  • BFRA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.84% yearly.
EPS Next Y-137.77%
EPS Next 2Y-19.62%
EPS Next 3Y24.2%
EPS Next 5Y12.07%
Revenue Next Year-5.25%
Revenue Next 2Y8.35%
Revenue Next 3Y4.65%
Revenue Next 5Y6.84%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BFRA Yearly Revenue VS EstimatesBFRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
BFRA Yearly EPS VS EstimatesBFRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -0.1 -0.2 -0.3 -0.4 -0.5

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BFRA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BFRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BFRA Price Earnings VS Forward Price EarningsBFRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -14.91
BFRA Per share dataBFRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

  • BFRA's earnings are expected to grow with 24.20% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.62%
EPS Next 3Y24.2%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for BFRA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

BIOFRONTERA AG

NASDAQ:BFRA (3/4/2022, 8:19:41 PM)

2.67

-0.28 (-9.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners0%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap151.44M
Revenue(TTM)27.99M
Net Income(TTM)-15.67M
Analysts80
Price Target14.22 (432.58%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.92
P/FCF N/A
P/OCF N/A
P/B 8.67
P/tB N/A
EV/EBITDA -14.91
EPS(TTM)-0.29
EYN/A
EPS(NY)-0.38
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.54
BVpS0.31
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -22.64%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -42.23%
PM (TTM) -55.98%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.26
Quick Ratio 1.13
Altman-Z -2.09
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.67%
EPS Next Y-137.77%
EPS Next 2Y-19.62%
EPS Next 3Y24.2%
EPS Next 5Y12.07%
Revenue 1Y (TTM)-15.27%
Revenue growth 3Y36.15%
Revenue growth 5Y48.96%
Sales Q2Q%14.13%
Revenue Next Year-5.25%
Revenue Next 2Y8.35%
Revenue Next 3Y4.65%
Revenue Next 5Y6.84%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

BIOFRONTERA AG / BFRA FAQ

What is the ChartMill fundamental rating of BIOFRONTERA AG (BFRA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to BFRA.


What is the valuation status of BIOFRONTERA AG (BFRA) stock?

ChartMill assigns a valuation rating of 1 / 10 to BIOFRONTERA AG (BFRA). This can be considered as Overvalued.


What is the profitability of BFRA stock?

BIOFRONTERA AG (BFRA) has a profitability rating of 4 / 10.


How financially healthy is BIOFRONTERA AG?

The financial health rating of BIOFRONTERA AG (BFRA) is 1 / 10.


What is the earnings growth outlook for BIOFRONTERA AG?

The Earnings per Share (EPS) of BIOFRONTERA AG (BFRA) is expected to decline by -137.77% in the next year.